Evaluation of the resistance of a geopolymer-based drug delivery system to tampering

International Journal of Pharmaceutics

Volumn 465, Issue 1-2, 2014, Pages 169-174

  Cai, Bing ^a   Engqvist, Håkan ^a   Bredenberg, Susanne ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

Abuse; Controlled release; Formulation; Opioids; Oral drug delivery; Resistance to tampering

Indexed keywords

DRUG CARRIER; GEOPOLYMER; OPIATE; OXYCODONE; UNCLASSIFIED DRUG; DELAYED RELEASE FORMULATION; NARCOTIC ANALGESIC AGENT; POLYMER; SOLVENT; TABLET;

ARTICLE; COMPARATIVE STUDY; COMPRESSIVE STRENGTH; CONTROLLED RELEASE FORMULATION; DRUG ABUSE; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG ISOLATION; DRUG RELEASE; DRUG RESISTANCE; DRUG SOLUBILITY; ENTERIC COATED TABLET; PRIORITY JOURNAL; SOLVENT EXTRACTION; CHEMISTRY; DELAYED RELEASE FORMULATION; DRUG USE; EVALUATION STUDY; HUMAN; ISOLATION AND PURIFICATION; MEDICINAL CHEMISTRY; OPIOID-RELATED DISORDERS; ORAL DRUG ADMINISTRATION; PHARMACEUTICS; PROCEDURES; SOLUBILITY; TABLET; TEMPERATURE; TIME; CONTROLLED STUDY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; SCANNING ELECTRON MICROSCOPY; SUSTAINED DRUG RELEASE; SYNTHESIS;

ADMINISTRATION, ORAL; ANALGESICS, OPIOID; CHEMISTRY, PHARMACEUTICAL; COMPRESSIVE STRENGTH; DELAYED-ACTION PREPARATIONS; DRUG CARRIERS; DRUG COMPOUNDING; DRUG USERS; HUMANS; OPIOID-RELATED DISORDERS; OXYCODONE; POLYMERS; SOLUBILITY; SOLVENTS; TABLETS; TECHNOLOGY, PHARMACEUTICAL; TEMPERATURE; TIME FACTORS;

EID: 84898597538     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2014.02.029     Document Type: Article

References (35)

1. Anonymous Meeting background material, Joint meeting of the anesthetic and life support drug advisory committee and drug safety and risk management advisory committee 2008 Purdue Pharma L.P. Stamford
2. Anonymous NDA 22-324 Remoxy XRT (oxycodone controlled-release) Capsules CII, Advisory committee briefing materials for the anesthetic life support drugs advisory committee meeting of November 13, 2008 2008 DURECT Corporation San Mateo
3. Anonymous The DAWN Report: Trends in Emergency Department Visits Involving Nonmedical Use of Narcotic Pain Relievers 2010 Drug Abuse Warning Network (DAWN), Substance Abuse and Mental Health Services Administration, Office of Applied Studies Rockville
4. Anonymous Center for Drug Evaluation and Research (CDER) F.a.D.A. U.S. Department of Health and Human Services Guidance for Industry Assessment of Abuse Potential of Drugs Rockville 2010 http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/UCM198650.pdf
5. Anonymous Guidance for Industry Abuse-Deterrent Opioids - Evaluation and Labeling, Draft Guidance U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Rockville 2013 http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/UCM334743.pdf
6. Arkenau-Maric, E., Bartholomäus, J., Kugelmann, H., 2013. Abuse-proofed dosage form, US 20130171075 A1.
7. J.H. Bartholomaeus, E. Arkenau-Marić, and E. Galia Opioid extended-release tablets with improved tamper-resistant properties Expert Opin. Drug Deliv. 9 2012 879 891
8. Bastin, R.J., Lithgow, B.H., 2001. Abuse resistant tablets, US 6309668 B1.
9. P. Costa, and J.M. Sousa Lobo Modeling and comparison of dissolution profiles Eur. J. Pharm. Sci. 13 2001 123 133 (Pubitemid 32288781)
10. K.E. Dunn, S.C. Sigmon, M.R. McGee, S.H. Heil, and S.T. Higgins Evaluation of ongoing oxycodone abuse among methadone-maintained patients J. Subst. Abuse Treat. 35 2008 451 456
11. H.M. Fadda, M.A.M. Mohamed, and A.W. Basit Impairment of the in vitro drug release behaviour of oral modified release preparations in the presence of alcohol Int. J. Pharm. 360 2008 171 176
12. J. Forsgren, C. Pedersen, M. Strømme, and H. Engqvist Synthetic geopolymers for controlled delivery of oxycodone: adjustable and nanostructured porosity enables tunable and sustained drug release PLoS ONE 6 2011 e17759
13. P.A. Goliber Benchtop Evaluations of Tampering with Pharmaceutical Dosage Forms Opioid Abuse Resistance Conference 2005
14. Habib, W.A., Hamed, E., Zepeda, M.A.V., 2013. Abuse resistant drug formulation, US 8445018 B2.
15. E. Jämstorp, J. Forsgren, S. Bredenberg, H. Engqvist, and M. Strømme Mechanically strong geopolymers offer new possibilities in treatment of chronic pain J. Control. Release 146 2010 370 377
16. E. Jämstorp, M. Strømme, and G. Frenning Modeling structure-function relationships for diffusive drug transport in inert porous geopolymer matrices J. Pharm. Sci. 100 2011 4338 4348
17. E. Jämstorp, M. Strømme, and S. Bredenberg Influence of drug distribution and solubility on the release from geopolymer pellets - a FEM study J. Pharm. Sci. 101 2012 1803 1810
18. E. Kalso Oxycodone J. Pain Symptom Manage. 29 2005 47 56
19. N. Katz, R.C. Dart, E. Bailey, J. Trudeau, E. Osgood, and F. Paillard Tampering with prescription opioids: nature and extent of the problem. health consequences, and solutions Am. J. Drug Alcohol Abuse 37 2011 205 217
20. B.M. Kuehn Opioid prescriptions soar: increase in legitimate use as well as abuse J. Am. Med. Assoc. 297 2007 249 251 (Pubitemid 46143290)
21. P.-C. Kuo, J.-C. Liu, S.-F. Chang, and Y.W. Chien In-vitro transdermal permeation of oxycodone: (I) effect of PH, delipidization and skin stripping Drug Dev. Ind. Pharm. 15 1989 1199 1215 (Pubitemid 19194654)
22. L. Manchikanti, and A. Singh Therapeutic opioids: a ten-year perspective on the complexities and complications of the escalating use, abuse, and nonmedical use of opioids Pain Physician 11 2008 S63 S88 (Pubitemid 351682079)
23. R.S. Mansbach, and R.A. Moore Jr. Formulation considerations for the development of medications with abuse potential Drug Alcohol Depend. 83 Supplement 1 2006 S15 S22
24. D.J. Mastropietro, and H. Omidian Current approaches in tamper-resistant and abuse-deterrent formulations Drug Dev. Ind. Pharm. 39 2012 611 624
25. H. Oudadesse, A.C. Derrien, M. Lefloch, and J. Davidovits MAS-NMR studies of geopolymers heat-treated for applications in biomaterials field J. Mater. Sci. 42 2007 3092 3098 (Pubitemid 46738226)
26. Rahmouni, M., Gervais, S., Sant, V., Smith, D., Duffayet, F., Rustom, S., El-Jammal, A., Ndong, J.M., Bichara, A., 2013. Misuse preventative, controlled release formulation, US 20130344142 A1.
27. A. Rosenblum, M. Parrino, S.H. Schnoll, C. Fong, C. Maxwell, C.M. Cleland, S. Magura, and J.D. Haddox Prescription opioid abuse among enrollees into methadone maintenance treatment Drug Alcohol Depend. 90 2007 64 71 (Pubitemid 46935374)
28. W. Roth, B. Setnik, M. Zietsch, A. Burst, J. Breitenbach, E. Sellers, and D. Brennan Ethanol effects on drug release from Verapamil Meltrex®, an innovative melt extruded formulation Int. J. Pharm. 368 2009 72 75
29. Shah, M.S., Difalco, R.J., 2011. Abuse resistant drugs, method of use and method of making, WO 2009023672 A2.
30. J. Siepmann, and F. Siepmann Modeling of diffusion controlled drug delivery J. Control. Release 161 2012 351 362
31. S.P. Stanos, P. Bruckenthal, and R.L. Barkin Strategies to reduce the tampering and subsequent abuse of long-acting opioids: potential risks and benefits of formulations with physical or pharmacologic deterrents to tampering Mayo Clin. Proc. 87 2012 683 694
32. Vaghefi, F., Liversidge, G., Ruddy, S., Cooper, E., 2014. Abuse-resistant pharmaceutical compositions, US 8623412 B2.
33. L. Webster, B. St Marie, B. McCarberg, S.D. Passik, S.J. Panchal, and E. Voth Current status and evolving role of abuse-deterrent opioids in managing patients with chronic pain J. Opioid Manage. 7 2011 235 245
34. L.R. Webster PTI-821: sustained-release oxycodone using gel-cap technology Expert Opin. Investig. Drugs 16 2007 359 366 (Pubitemid 46394860)
35. Yum, S.I., Chao, W., Su, H.C., Fu, R., Zamloot, M., 2013. Oral pharmaceutical dosage forms, US 8415401 B2.